繁體中文
返回
- English
- 繁體中文
- 简体中文
- 深色
- 淺色
立即開戶
牛牛AI助理已提取核心訊息
Heart Test Laboratories, a Texas-based company, has filed a Form 8-K with the SEC, reporting significant corporate actions as of May 6, 2024. The company, which trades under the symbol HSCS on the Nasdaq Stock Market, has been notified by Nasdaq of non-compliance with the Minimum Bid Price Requirement since August 2, 2023. Despite being granted an extension until July 29, 2024, to meet this requirement, Heart Test Laboratories received a staff determination on May 9, 2024, to delist its securities due to the common stock's closing bid price falling to $0.10 or less for ten consecutive trading days. The company plans to appeal this determination and has until May 16, 2024, to file a hearing request, which will stay the delisting pending the Panel's decision. In...Show More
Heart Test Laboratories, a Texas-based company, has filed a Form 8-K with the SEC, reporting significant corporate actions as of May 6, 2024. The company, which trades under the symbol HSCS on the Nasdaq Stock Market, has been notified by Nasdaq of non-compliance with the Minimum Bid Price Requirement since August 2, 2023. Despite being granted an extension until July 29, 2024, to meet this requirement, Heart Test Laboratories received a staff determination on May 9, 2024, to delist its securities due to the common stock's closing bid price falling to $0.10 or less for ten consecutive trading days. The company plans to appeal this determination and has until May 16, 2024, to file a hearing request, which will stay the delisting pending the Panel's decision. In an effort to regain compliance, Heart Test Laboratories has initiated a reverse stock split of its common stock and warrants at a ratio of 1-for-100, subject to Nasdaq's confirmation. The reverse stock split is expected to be effected in the market shortly after confirmation from Nasdaq. The company's stockholders approved this action at the annual meeting on January 17, 2024, and the Board has selected the reverse stock split ratio. The reverse stock split will not change the number of authorized shares or the par value of the common stock but will adjust the number of shares underlying outstanding equity awards, warrants, and convertible securities. Stockholders holding shares in electronic form at brokerage firms or in book-entry form with the transfer agent will not need to take any action.
總部位於德克薩斯州的Heart Test Laboratories公司已向美國證券交易委員會提交了8-K表格,報告了截至2024年5月6日的重大公司行動。該公司在納斯達克股票市場上以HSCS的代碼進行交易,自2023年8月2日以來,納斯達克已通知該公司未遵守最低出價要求。儘管爲了滿足這一要求,心臟測試實驗室獲准延長至2024年7月29日,但由於普通股的收盤價連續十個交易日跌至0.10美元或以下,Heart Test Laboratories於2024年5月9日收到了工作人員的決定,決定將其證券退市。該公司計劃對該裁決提出上訴,並且必須在2024年5月16日之前提出聽證請求,在專家組做出決定之前...展開全部
總部位於德克薩斯州的Heart Test Laboratories公司已向美國證券交易委員會提交了8-K表格,報告了截至2024年5月6日的重大公司行動。該公司在納斯達克股票市場上以HSCS的代碼進行交易,自2023年8月2日以來,納斯達克已通知該公司未遵守最低出價要求。儘管爲了滿足這一要求,心臟測試實驗室獲准延長至2024年7月29日,但由於普通股的收盤價連續十個交易日跌至0.10美元或以下,Heart Test Laboratories於2024年5月9日收到了工作人員的決定,決定將其證券退市。該公司計劃對該裁決提出上訴,並且必須在2024年5月16日之前提出聽證請求,在專家組做出決定之前,該請求將暫停除名。爲了恢復合規性,Heart Test Laboratories已開始以1比100的比例對其普通股和認股權證進行反向股票拆分,但須經納斯達克確認。反向股票拆分預計將在納斯達克確認後不久在市場上生效。該公司的股東在2024年1月17日的年會上批准了這一行動,董事會選擇了反向股票拆分比例。反向股票拆分不會改變授權股票的數量或普通股的面值,但會調整已發行股票獎勵、認股權證和可轉換證券所依據的股票數量。以電子形式在經紀公司持有股票或以賬面記賬形式向過戶代理人持有股票的股東無需採取任何行動。
有用
沒用
譯文內容由第三人軟體翻譯。
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
資訊熱榜
更新時間